Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems

BACKGROUND: “Biomarker-driven targeted therapy,” the practice of tailoring patients’ treatment to the expression/activity levels of disease-specific genes/proteins, remains challenging. For example, while the anti-ERBB2 monoclonal antibody, trastuzumab, was first developed using well-characterized,...

詳細記述

保存先:
書誌詳細
出版年:BMC Cancer
主要な著者: Chang, Hae Ryung, Park, Hee Seo, Ahn, Young Zoo, Nam, Seungyoon, Jung, Hae Rim, Park, Sungjin, Lee, Sang Jin, Balch, Curt, Powis, Garth, Ku, Ja-Lok, Kim, Yon Hui
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2016
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784390/
https://ncbi.nlm.nih.gov/pubmed/26955870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2232-2
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料